376 related articles for article (PubMed ID: 15557593)
1. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis as a therapeutic target in malignant gliomas.
Chi AS; Sorensen AG; Jain RK; Batchelor TT
Oncologist; 2009 Jun; 14(6):621-36. PubMed ID: 19487335
[TBL] [Abstract][Full Text] [Related]
3. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
[TBL] [Abstract][Full Text] [Related]
4. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.
Mayer EL; Isakoff SJ; Klement G; Downing SR; Chen WY; Hannagan K; Gelman R; Winer EP; Burstein HJ
Breast Cancer Res Treat; 2012 Nov; 136(1):169-78. PubMed ID: 23001754
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.
Russell S; Duquette M; Liu J; Drapkin R; Lawler J; Petrik J
FASEB J; 2015 Feb; 29(2):576-88. PubMed ID: 25395453
[TBL] [Abstract][Full Text] [Related]
6. Imatinib Sets Pericyte Mosaic in the Retina.
Kovács-Öller T; Ivanova E; Szarka G; Tengölics ÁJ; Völgyi B; Sagdullaev BT
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260484
[TBL] [Abstract][Full Text] [Related]
7. Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.
Holtz DO; Krafty RT; Mohamed-Hadley A; Zhang L; Alagkiozidis I; Leiby B; Guo W; Gimotty PA; Coukos G
J Transl Med; 2008 Jan; 6():2. PubMed ID: 18182107
[TBL] [Abstract][Full Text] [Related]
8. Low-dose metronomic cisplatin as an antiangiogenic and anti-inflammatory strategy for cancer.
Kikuchi H; Maishi N; Yu L; Jia Z; Li C; Sato M; Takeda R; Ishizuka K; Hida Y; Shinohara N; Hida K
Br J Cancer; 2024 Feb; 130(2):336-345. PubMed ID: 38036665
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma.
Ganslmayer M; Zimmermann A; Zopf S; Herold C
World J Gastroenterol; 2011 Aug; 17(31):3623-9. PubMed ID: 21987609
[TBL] [Abstract][Full Text] [Related]
10. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules.
Banchi M; Cox MC; Bocci G
Cancer Lett; 2024 Jun; 591():216900. PubMed ID: 38636896
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal examination of perfusion and angiogenesis markers in primary colorectal tumors shows distinct signatures for metronomic and maximum-tolerated dose strategies.
Mundo AI; Muhammad A; Balza K; Nelson CE; Muldoon TJ
Neoplasia; 2022 Oct; 32():100825. PubMed ID: 35901621
[TBL] [Abstract][Full Text] [Related]
12. Evolution and contemporary role of metronomic chemotherapy in the treatment of neuroblastoma.
Chou SW; Chang HH
Cancer Lett; 2024 Apr; 588():216617. PubMed ID: 38311055
[TBL] [Abstract][Full Text] [Related]
13. A mathematical model to study low-dose metronomic scheduling for chemotherapy.
Arora G; Bairagi N; Chatterjee S
Math Biosci; 2024 Jun; 372():109186. PubMed ID: 38580078
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic approaches for the treatment of advanced synovial sarcomas.
Do K; Doroshow JH; Kummar S
Curr Opin Oncol; 2012 Jul; 24(4):425-30. PubMed ID: 22572725
[TBL] [Abstract][Full Text] [Related]
15. Metronomic Chemotherapy in Elderly Patients.
Bandini A; Calabrò PF; Banchi M; Orlandi P; Bocci G
Curr Oncol Rep; 2024 Apr; 26(4):359-376. PubMed ID: 38448722
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer therapeutics that target signaling pathways: an update.
Ray MR; Jablons D; He B
Expert Rev Respir Med; 2010 Oct; 4(5):631-45. PubMed ID: 20923341
[TBL] [Abstract][Full Text] [Related]
17. Low-dose Cisplatin Induces Tumor Growth
Cheng K; Tang F; Liu X; Wei J; You H; DU Q; Lin Y; Feng W
Anticancer Res; 2023 Dec; 43(12):5509-5522. PubMed ID: 38030193
[TBL] [Abstract][Full Text] [Related]
18. Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions.
Thakur A; Rana M; Mishra A; Kaur C; Pan CH; Nepali K
Eur J Med Chem; 2024 Jun; 272():116472. PubMed ID: 38728867
[TBL] [Abstract][Full Text] [Related]
19. Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization.
Nikmaneshi MR; Jain RK; Munn LL
PLoS Comput Biol; 2023 Jun; 19(6):e1011131. PubMed ID: 37289729
[TBL] [Abstract][Full Text] [Related]
20. Metronomic chemotherapy offsets HIFα induction upon maximum-tolerated dose in metastatic cancers.
Schito L; Rey S; Xu P; Man S; Cruz-Muñoz W; Kerbel RS
EMBO Mol Med; 2020 Sep; 12(9):e11416. PubMed ID: 32686360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
